LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
5.89
+0.10 (1.73%)
At close: Jul 2, 2026, 4:00 PM EDT
5.90
+0.01 (0.17%)
After-hours: Jul 2, 2026, 6:55 PM EDT
LENZ Therapeutics Revenue
LENZ Therapeutics had revenue of $1.90M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $20.99M. In the year 2025, LENZ Therapeutics had annual revenue of $19.09M.
Revenue (ttm)
$20.99M
Revenue Growth
n/a
P/S Ratio
8.80
Revenue / Employee
$138,086
Employees
152
Market Cap
184.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.09M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 15.00M | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 76.38M |
| Tonix Pharmaceuticals Holding | 17.56M |
| MediWound | 14.48M |
| Caribou Biosciences | 11.20M |
| Equillium | 4.39M |
| Humacyte | 2.02M |
| Oramed Pharmaceuticals | 2.00M |
| Milestone Pharmaceuticals | 1.78M |
LENZ News
- 9 days ago - LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand - GlobeNewsWire
- 26 days ago - Lenz announces Everest Medicines acquired rights to develop VIZZ in China - TheFly
- 26 days ago - LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China - GlobeNewsWire
- 5 weeks ago - LENZ Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Lenz Therapeutics price target lowered to $20 from $26 at Citi - TheFly
- 7 weeks ago - LENZ Therapeutics trading halted, volatility trading pause - TheFly
- 7 weeks ago - LENZ Therapeutics trading resumes - TheFly
- 7 weeks ago - Lenz Therapeutics price target raised to $31 from $29 at BofA - TheFly